The Hypoxia-Inducible Factor 2 α N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In Vivo
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor, consisting of an alpha subunit and a beta subunit, that controls cellular responses to hypoxia. HIFalpha contains two transcriptional activation domains called the N-terminal transactivation domain (NTAD) and the C-terminal transactivation domain (CTAD). HIFalpha is destabilized by prolyl hydroxylation catalyzed by EglN family members. In addition, CTAD function is inhibited by asparagine hydroxylation catalyzed by FIH1. Both hydroxylation reactions are linked to oxygen availability. The von Hippel-Lindau tumor suppressor protein (pVHL) is frequently mutated in kidney cancer and is part of the ubiquitin ligase complex that targets prolyl hydroxylated HIFalpha for destruction. Recent studies suggest that HIF2alpha plays an especially important role in promoting tumor formation by pVHL-defective renal carcinoma cells among the three HIFalpha paralogs. Here we dissected the relative contribution of the two HIF2alpha transactivation domains to hypoxic gene activation and renal carcinogenesis and investigated the regulation of the HIF2alpha CTAD by FIH1. We found that the HIF2alpha NTAD is capable of activating both artificial and naturally occurring HIF-responsive promoters in the absence of the CTAD. Moreover, we found that the HIF2alpha CTAD, in contrast to the HIF1alpha CTAD, is relatively resistant to the inhibitory effects of FIH1 under normoxic conditions and that, perhaps as a result, both the NTAD and CTAD cooperate to promote renal carcinogenesis in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, HIF2α is relatively resistant to FIH1-mediated inactivation compared to HIF1α (Bracken et al., 2006; Yan et al., 2007).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Yan et al., 2007
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 2×
“Most solid tumors contain hypoxic regions in which HIF is stabilized and active, as determined by the induction of HIF target genes that promote survival in a hypoxia environment (18).”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“786-O renal carcinoma cell subclones stably transfected with pRc-CMV-HA-VHL (WT7) ( 27 ) were grown in DMEM containing 10% fetal clone I (HyClone) containing 1 mg/ml G418 in a 37°C, 10% CO2 incubator.”
MethodEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 1×
“These genes include genes that control angiogenesis (such as vascular endothelial growth factor [VEGF]), energy metabolism (for example, the glucose transporter 1 [GLUT1] and carbonic anhydrase IX [CAIX]), erythropoiesis (such as erythropoietin [EPO]), and mitogenesis (for example, transforming growth factor and plate…”
BackgroundRegulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914 · cited 1×
“HIF (hypoxia-inducible factor) is a master transcriptional regulator of hypoxia-inducible genes and is composed of the subunit HIF1, or one of its paralogs HIF2 or HIF3, and a HIF subunit, such as HIF1 (also called the aryl hydrocarbon receptor nuclear translocator [ARNT]) (12, 14, 17, 20, 50 , 53).”
BackgroundHIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · cited 4×
“Mutation of the relevant hydroxylation sites renders these GAL4 fusions constitutively active and insensitive to oxygen (19, 36, 37 ).”
BackgroundInfluentialLando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550 · cited 8×
“Like the EglN prolyl hydroxylases, FIH1 is an Fe(II) and 2-oxoglutarate-dependent dioxygenase, and its activity can be blocked with competitive inhibitors of 2-oxoglutarate and with iron chelators (19, 36).”
BackgroundInfluential
Cited by
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
“Moreover, HIF2a is relatively resistant to FIH1-mediated inactivation compared to HIF1a (Bracken et al., 2006; Yan et al., 2007).”
BackgroundSelf-citationHeddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
Kaelin Jr, W. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2502 · Cited by 726
“HIF2α is less sensitive than HIF1α to inhibition by FIH1, which should be active in oxygenated VHL-defective cell”
BackgroundSelf-citationZhou, W., Choi, M., Margineantu, D., Margaretha, L., Hesson, J., Cavanaugh, C., Blau, C. A., Horwitz, M. S., Hockenbery, D., Ware, C., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.71 · Cited by 555
“To obtain constitutively stable expression HIF1 a protein, non-degrad-able HIF1 a overexpressing plasmid (Addgene plasmid 19005) was used, in which two of the proline sites of HIF1 a cDNAwere changed to alanine as described previously (Yan et al , 2007).”
Pietras, A., Katz, A. M., Ekström, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, N. M., Huse, J. T., & Holland, E. C. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.005 · Cited by 540
“Oxygen-insensitive mutants of HIF1A and HIF2A (Yan et al., 2007) were obtained from Addgene (#18955 and #18956, respectively).”
BackgroundMethodStabilization of HIF-1α is critical to improve wound healing in diabetic mice
Botusan, I. R., Sunkari, V. G., Savu, O., Catrina, A. I., Grünler, J., Lindberg, S., Pereira, T., Ylä-Herttuala, S., Poellinger, L., Brismar, K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805230105 · Cited by 533
“Interestingly, a central pathogenic role for the NTAD without any additional regulatory effect from the CTAD has also recently been suggested for HIF-2 -driven renal carcinogenesis (26).”
BackgroundHIF Induces Human Embryonic Stem Cell Markers in Cancer Cells
Mathieu, J., Zhang, Z., Zhou, W., Wang, A. J., Heddleston, J. M., Pinna, C. M. A., Hubaud, A., Stadler, B., Choi, M., Bar, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3320 · Cited by 508
Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene
Shen, C., Beroukhim, R., Schumacher, S. E., Zhou, J., Chang, M., Signoretti, S., & Kaelin, W. G. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0098 · Cited by 413
Self-citationThe VHL/HIF axis in clear cell renal carcinoma
Shen, C., & Kaelin, W. G. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.001 · Cited by 388
Self-citationChen, J., Imanaka, N., Chen, J., & Griffin, J. D. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605486 · Cited by 346
“pcDNA3/HIF-1a (P402A/P564A) and pcDNA3/HIF-2a (P405A/ P531A) constructs were described earlier (Yan et al, 2007).”
Biology of hypoxia-inducible factor-2α in development and disease
Patel, S. A., & Simon, M. C. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.17 · Cited by 327
VHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M., van Vlodrop, I. J., Vermeulen, P. B., Soetekouw, P. M., van Engeland, M., & de Bruïne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 316
“Nevertheless, it was recently found that the HIF-2α CTAD, in contrast to HIF-1α, is relatively resistant to the inhibitory effects of FIH under normoxic conditions [12].”
BackgroundResultSomatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure
Minamishima, Y. A., Moslehi, J., Bardeesy, N., Cullen, D., Bronson, R. T., & Kaelin, W. G. (2008) · Blood · doi:10.1182/blood-2007-10-117812 · Cited by 294
Self-citationWang, H., Bian, S., & Yang, C. S. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr218 · Cited by 261
Zhang, P., Yao, Q., Lu, L., Li, Y., Chen, P.-J., & Duan, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.011 · Cited by 231
“A stabilized human HIF-1a plasmid (i.e., HIF-1a’ thereafter) was used as a control (Yan et al., 2007).”
Mathieu, J., Zhou, W., Xing, Y., Sperber, H., Ferreccio, A., Agoston, Z., Kuppusamy, K. T., Moon, R. T., & Ruohola-Baker, H. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.012 · Cited by 209
“Reprogramming Process Requires Controlled HIF2a Activity Because hypoxia is beneficial for reprogramming and HIF2a and HIF1a are required for the process, we tested whether constitutive stabilization of HIF1a and/or HIF2a would enhance iPSC generation by overexpressing nondegradable forms of HIF1a and HIF2a during rep…”
BackgroundMethodInfluentialSuppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo
Sjölund, J., Johansson, M., Manna, S., Norin, C., Pietras, A., Beckman, S., Nilsson, E., Ljungberg, B., & Axelson, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32086 · Cited by 182
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
Yin, M., Guo, Y., Hu, R., Cai, W. L., Li, Y., Pei, S., Sun, H., Peng, C., Li, J., Ye, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15290-0 · Cited by 171
Self-citationThe HIF pathway and erythrocytosis
Lee, F. S., & Percy, M. J. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130321 · Cited by 177
Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanova, I., Yang, C., Zhuang, Z., & Pacak, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 172
Molecular targeting of hypoxia in radiotherapy
Rey, S., Schito, L., Koritzinsky, M., & Wouters, B. G. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.10.002 · Cited by 172
Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer
Blair, L. P., Cao, J., Zou, M. R., Sayegh, J., & Yan, Q. (2011) · Cancers · doi:10.3390/cancers3011383 · Cited by 169
Self-citationParathath, S., Mick, S. L., Feig, J. E., Joaquin, V., Grauer, L., Habiel, D. M., Gassmann, M., Gardner, L. B., & Fisher, E. A. (2011) · Circulation Research · doi:10.1161/circresaha.111.246363 · Cited by 166
A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo
Minamishima, Y. A., Moslehi, J., Padera, R. F., Bronson, R. T., Liao, R., & Kaelin, W. G. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00331-09 · Cited by 161
“However, the inactivation of Phd2 alone transcriptionally activates a subset of HIF target genes (35, 52), presumably because these genes are driven by the HIF NTAD or because they are responsive primarily to HIF2 , which is fairly insensitive to FIH1 compared to HIF1 (7, 54).”
BackgroundSelf-citationSchödel, J., Bardella, C., Sciesielski, L. K., Brown, J. M., Pugh, C. W., Buckle, V., Tomlinson, I. P., Ratcliffe, P. J., & Mole, D. R. (2012) · Nature Genetics · doi:10.1038/ng.2204 · Cited by 158
Niu, X., Zhang, T., Liao, L., Zhou, L., Lindner, D. J., Zhou, M., Rini, B., Yan, Q., & Yang, H. (2012) · Oncogene · doi:10.1038/onc.2011.266 · Cited by 155
“O VHLþ /þ cells were infected with empty retrovirus, retrovirus expressing either a stable and transcriptionally active HIF2a mutant (HIF2a-dPA) or a stable but transcriptionally inactive HIF2a mutant (HIF2a-PA-dTA) (described in Yan et al., 2007).”
BackgroundSelf-citationDuodenal Cytochrome b (DCYTB) in Iron Metabolism: An Update on Function and Regulation
Lane, D., Bae, D.-H., Merlot, A., Sahni, S., & Richardson, D. (2015) · Nutrients · doi:10.3390/nu7042274 · Cited by 150
“However, in the case of HIF2α, the inhibitory effect of FIH1 appears to be minor [128].”
Wang, X., de Carvalho Ribeiro, M., Iracheta‐Vellve, A., Lowe, P., Ambade, A., Satishchandran, A., Bukong, T., Catalano, D., Kodys, K., & Szabo, G. (2019) · Hepatology · doi:10.1002/hep.30215 · Cited by 146
Basu, R. K., Hubchak, S. C., Hayashida, T., Runyan, C. E., Schumacker, P. T., & Schnaper, H. W. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00335.2010 · Cited by 146
Sox17 is required for endothelial regeneration following inflammation-induced vascular injury
Liu, M., Zhang, L., Marsboom, G., Jambusaria, A., Xiong, S., Toth, P. T., Benevolenskaya, E. V., Rehman, J., & Malik, A. B. (2019) · Nature Communications · doi:10.1038/s41467-019-10134-y · Cited by 143
EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection
Olenchock, B. A., Moslehi, J. J., Baik, A. H., Davidson, S. M., Williams, J., Gibson, W. J., Chakraborty, A. A., Pierce, K. A., Miller, C. M., Hanse, E. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.006 · Cited by 150
“The 3XHRE luciferase reporter (Yan et al., 2007) was shuttled into a promoterless lentivirus.”
Self-citationIn vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas
Toledo, R. A., Qin, Y., Srikantan, S., Morales, N. P., Li, Q., Deng, Y., Kim, S.-W., Pereira, M. A. A., Toledo, S. P. A., Su, X., et al. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0101 · Cited by 134
“It is also possible that the transcriptional transactivation properties of the amino acid sequence surrounding the Pro531 region may contribute to mutation-specific differences (Kondo et al. 2003, Yan et al. 2007).”
BackgroundLack of oxygen in articular cartilage: consequences for chondrocyte biology
Lafont, J. E. (2010) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2010.00707.x · Cited by 157
“Recently, it has been described that an asparagine residue located in the CTAD (on the Asn803 of the human HIF-1a) is also hydroxylated by an asparaginyl hydroxylase (Factor inhibiting HIF, FIH) inactivating HIF (Mahon et al. 2001; Lando et al. 2002).”
BackgroundSayegh, J., Cao, J. P., Zou, M. R., Morales, A., Blair, L. P., Norcia, M., Hoyer, D., Tackett, A. J., Merkel, J. S., & Yan, Q. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.419861 · Cited by 138
“Primers specific for ACTB were described previously (27).”
MethodSelf-citationBouaziz, W., Sigaux, J., Modrowski, D., Devignes, C.-S., Funck‐Brentano, T., Richette, P., Ea, H., Provot, S., Cohen-Solal, M. E., & Haÿ, E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514854113 · Cited by 133
Johansson, E., Grassi, E. S., Pantazopoulou, V., Tong, B., Lindgren, D., Berg, T. J., Pietras, E. J., Axelson, H., & Pietras, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.049 · Cited by 121
Kaposi's Sarcoma Herpesvirus MicroRNAs Induce Metabolic Transformation of Infected Cells
Yogev, O., Lagos, D., Enver, T., & Boshoff, C. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004400 · Cited by 130
“We therefore expressed the HIF1a P402A/P564A stable mutant in LEC [67] (Figure S4D).”
Treatment of kidney cancer: Insights Provided by the VHL Tumor‐Suppressor Protein
Kaelin, W. G. (2009) · Cancer · doi:10.1002/cncr.24232 · Cited by 129
“However, recent studies suggest that HIF2a is less sensitive than HIF-1a to the inhibitory effects of FIH1(28,29) and that, accordingly, both the HIF-2aNTAD and CTAD contribute to tumorigenesis.(29) In addition, it is becoming clear that HIF-1a, more so than HIF2-a, can undergo proteasomal degradation in the absence o…”
BackgroundSelf-citationMTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma
Green, N. H., Galvan, D. L., Badal, S. S., Chang, B. H., LeBleu, V. S., Long, J., Jonasch, E., & Danesh, F. R. (2019) · Oncogene · doi:10.1038/s41388-019-0869-4 · Cited by 116
mRNA-to-protein translation in hypoxia
Chee, N. T., Lohse, I., & Brothers, S. P. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0968-4 · Cited by 126
“The absence of C-TAD in HIF3α suggests a secondary function independent of its transcriptional activity [17, 33].”
BackgroundTamama, K., Kawasaki, H., Kerpedjieva, S. S., Guan, J., Ganju, R. K., & Sen, C. K. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22961 · Cited by 97
“Retrovirus expression vector of the constitutively active (stable) forms of HIF-1a (HAHIF1alpha P402A/P564A-pBabe-puro) and HIF-2a (HA-HIF2alphaP405A/P531A-pBabe-puro) (Addgene plasmid 19005&19006) were courtesy of Dr. Kaelin at the Harvard Medical School (Boston, MA) [Yan et al., 2007].”
BackgroundMethodInfluentialTwo sides to every story: the HIF-dependent and HIF-independent functions of pVHL
Li, M., & Kim, W. Y. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01238.x · Cited by 109
“Both HIF1 and HIF2 have two transcriptional activation domains, the N-terminal transactivation domain (NTAD) and the C-terminal transactivation domain (CTAD), which activate target genes upon DNA binding [12].”
BackgroundInfluentialHIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis
Meléndez‐Rodríguez, F., Urrutia, A. A., Lorendeau, D., Rinaldi, G., Roche, O., Böğürcü, N., Ortega‐Muelas, M., Mesa‐Ciller, C., Turiel, G., Bouthelier, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.106 · Cited by 106
Das, B., Pal, B., Bhuyan, R., Li, H., Sarma, A., Gayan, S., Talukdar, J., Sandhya, S., Bhuyan, S., Gogoi, G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2847 · Cited by 92
“HIF-2α-P405A/P531A (45) (gift from Professor William Kaelin (addgene plasmid #18955 and #18956) and confirmed by Western Blot.”
BackgroundA general map of iron metabolism and tissue-specific subnetworks
Hower, V., Mendes, P., Torti, F. M., Laubenbacher, R., Akman, S., Shulaev, V., & Torti, S. V. (2009) · Molecular BioSystems · doi:10.1039/b816714c · Cited by 91
Baumann, B., Hayashida, T., Liang, X., & Schnaper, H. W. (2016) · Kidney International · doi:10.1016/j.kint.2016.05.026 · Cited by 93
GATA3 interacts with and stabilizes HIF-1α to enhance cancer cell invasiveness
Lin, M.-C., Lin, J., Hsu, C.-L., Juan, H., Lou, P., & Huang, M.-C. (2017) · Oncogene · doi:10.1038/onc.2017.8 · Cited by 94
Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α–Dependent Pathway in Multiple Myeloma
Zhang, J., Sattler, M., Tonon, G., Grabher, C., Lababidi, S., Zimmerhackl, A., Raab, M. S., Vallet, S., Zhou, Y., Cartron, M.-A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4603 · Cited by 93
Joshi, H. P., Subramanian, I. V., Schnettler, E. K., Ghosh, G., Rupaimoole, R., Evans, C., Saluja, M., Jing, Y., Cristina, I., Roy, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317242111 · Cited by 87
“The mutant P402A/P564A HIF1α (P-to-A HIF1α) was acquired from Addgene [plasmid 18955; contributed by William Kaelin (Dana-Farber Cancer Center, Boston) (27)].”
Shenoy, N. K., & Pagliaro, L. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw241 · Cited by 92
Cell-Autonomous Metabolic Reprogramming in Hypoxia
Schito, L., & Rey, S. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.006 · Cited by 89
Lineage tracing and analog recording in mammalian cells by single-site DNA writing
Loveless, T. B., Grotts, J. H., Schechter, M. W., Forouzmand, E., Carlson, C. K., Agahi, B. S., Liang, G., Ficht, M., Liu, B., Xie, X., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00769-8 · Cited by 80
Kraus, R. J., Yu, X., Cordes, B.-L. A., Sathiamoorthi, S., Iempridee, T., Nawandar, D. M., Ma, S., Romero-Masters, J. C., McChesney, K., Lin, Z. N., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006404 · Cited by 84
García‐Bermúdez, J., Badgley, M. A., Prasad, S., Baudrier, L., Liu, Y., La, K., Soula, M., Williams, R. T., Yamaguchi, N., Hwang, R. F., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00583-z · Cited by 94
Wong, H. K., Fatimy, R. E., Onodera, C. S., Wei, Z., Yi, M., Mohan, A., Gowrisankaran, S., Karmali, P. P., Marcusson, E. G., Wakimoto, H., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.72 · Cited by 82
Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells
Onnis, B., Fer, N. D., Rapisarda, A., Perez, V. S., & Melillo, G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci59623 · Cited by 85
Stiehl, D. P., Bordoli, M. R., Abreu‐Rodríguez, I., Wollenick, K., Schraml, P., Gradin, K., Poellinger, L., Kristiansen, G., & Wenger, R. H. (2011) · Oncogene · doi:10.1038/onc.2011.417 · Cited by 86
“…stabilized HIF2a mutants promoted the growth of xenografted renal cell carcinoma cell tumors and KrasG12D-driven lung tumorigenesis in mice (Yan et al., 2007; Kim et al., 2009), whereas Hif2a deletion in the same lung cancer model likewise increased tumor burden (Mazumdar et al., 2010).”
BackgroundHypoxia-inducible factor (HIF) network: insights from mathematical models
Cavadas, M. A., Nguyen, L. K., & Cheong, A. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-42 · Cited by 74
“The HIF-α protein contains two independent transcriptional activation domains (N-TAD and C-TAD [43-46]).”
BackgroundSPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Hart, P. C., Chiyoda, T., Liu, X., Weigert, M., Curtis, M., Chiang, C.-Y., Loth, R. M., Lastra, R. R., McGregor, S. M., Locasale, J. W., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0409 · Cited by 77
“The constitutively active HIF1a (P402A/P564A) and HIF2a (P405A/P531A) plasmids were a gift from William Kaelin (27) obtained through Addgene (338299).”
BackgroundCurrent strategies and progress for targeting the “undruggable” transcription factors
Zhuang, J., Liu, Q., Wu, D., & Tie, L. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00852-9 · Cited by 79
“Meanwhile, within the C-terminal transactivation domain (CTAD) of HIF-2α, Asn847 can also be hydroxylated by the factor inhibiting HIF (FIH) enzyme, further decreasing HIF-2α activity by blocking its interactions to coactivators [28].”
BackgroundThe Contributions of HIF-Target Genes to Tumor Growth in RCC
Zhang, T., Niu, X., Liao, L., Cho, E.-A., & Yang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080544 · Cited by 75
“The transcriptional activity of the HIF2α was shown to be critical for its oncogenic activity [16,17], suggesting that the HIF-responsive genes were largely responsible for its ability to promote tumor growth.”
BackgroundRozen‐Zvi, B., Hayashida, T., Hubchak, S. C., Hanna, C., Platanias, L. C., & Schnaper, H. W. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00215.2013 · Cited by 70
Organ Protection by Hypoxia and Hypoxia‐Inducible Factors
Bernhardt, W. M., Warnecke, C., Willam, C., Tanaka, T., Wiesener, M. S., & Eckardt, K. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35012-x · Cited by 73
Evensen, N. A., Li, Y., Kuscu, C., Liu, J., Cathcart, J. M., Banach, A., ZHANG, Q., Li, E., Joshi, S., Yang, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3978 · Cited by 67
Hypoxia-inducible factor-2α and TGF-β signaling interact to promote normoxic glomerular fibrogenesis
Hanna, C., Hubchak, S. C., Liang, X., Rozen‐Zvi, B., Schumacker, P. T., Hayashida, T., & Schnaper, H. W. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00155.2013 · Cited by 63
Warfel, N. A., Sainz, A. G., Song, J. H., & Kraft, A. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1018 · Cited by 60
Hypoxic pathobiology of breast cancer metastasis
Schito, L., & Rey, S. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.05.004 · Cited by 68
Cardioprotective HIF-1α-frataxin signaling against ischemia-reperfusion injury
Nanayakkara, G., Alasmari, A. F., Mouli, S., Eldoumani, H., Quindry, J. C., McGinnis, G. R., Fu, X., Berlin, A., Peters, B. A., Zhong, J., et al. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00875.2014 · Cited by 66
Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma
Yu, Y.-C., Yu, Q., & Zhang, X. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.008 · Cited by 62
Voss, D. M., Spina, R., Carter, D. L., Lim, K. S., Jeffery, C. J., & Bar, E. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-04612-w · Cited by 62
Dahia, P. L. M., Clifton-Bligh, R. J., Gimenez‐Roqueplo, A., Robledo, M., & Jiménez, C. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0435 · Cited by 58
Tanaka, T., Yamaguchi, J., Higashijima, Y., & Nangaku, M. (2013) · The FASEB Journal · doi:10.1096/fj.13-231837 · Cited by 53
USP33 deubiquitinates and stabilizes HIF‐2alpha to promote hypoxia response in glioma stem cells
Zhang, A., Huang, Z., Tao, W., Zhai, K., Wu, Q., Rich, J. N., Zhou, W., & Bao, S. (2022) · The EMBO Journal · doi:10.15252/embj.2021109187 · Cited by 52
“A short list of DUBs such as USP20, USP28, and USP9X have been reported to regulate HIF1 a in response to hypoxia because they counteract polyubiquitination of HIF1 a mediated by VHL (Li et al , 2005; Troilo et al , 2014; Goto et al , 2015; Zhang et al , 2016; Sun et al , 2018).”
InfluentialHisada, T., Ayaori, M., Ohrui, N., Nakashima, H., Nakaya, K., Uto‐Kondo, H., Yakushiji, E., Takiguchi, S., Terao, Y., Miyamoto, Y., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs110 · Cited by 54
Dayan, F., Monticelli, M., Pouysségur, J., & Pécou, E. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.03.009 · Cited by 49
“Recently the role of FIH as a pure HIF inhibitor has been questioned (Dayan et al., 2006, 2008; Yan et al., 2007).”
BackgroundStone, J. K., Kim, J., Vukadin, L., Richard, A., Giannini, H. K., Lim, S., Tan, M., & Ahn, E.-Y. E. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006889 · Cited by 50
Kruppel‐like factor 6 promotes macrophage inflammatory and hypoxia response
Kim, G., Ng, H. P., Chan, E. R., & Mahabeleshwar, G. H. (2020) · The FASEB Journal · doi:10.1096/fj.201902221r · Cited by 48
BHLHE40 promotes macrophage pro‐inflammatory gene expression and functions
Zafar, A., Ng, H. P., Kim, G., Chan, E. R., & Mahabeleshwar, G. H. (2021) · The FASEB Journal · doi:10.1096/fj.202100944r · Cited by 58
The von Hippel‐Lindau Tumor Suppressor Protein: An Update
Kaelin, W. G. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35019-2 · Cited by 51
Self-citationHu, J., Yin, Z., Shen, W., Xie, Y., Zhu, T., Lü, P., Cai, Y., Kong, M., Heng, B. C., Zhou, Y., et al. (2016) · Stem Cells · doi:10.1002/stem.2306 · Cited by 46
NADPH oxidase NOX4 is a glycolytic regulator through mROS-HIF1α axis in thyroid carcinomas
Tang, P., Dang, H., Huang, J., Xu, T., Yuan, P., Hu, J., & Sheng, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-34154-8 · Cited by 45
Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma
Siebenthall, K. T., Miller, C. P., Vierstra, J. D., Mathieu, J., Tretiakova, M., Reynolds, A. P., Sandstrom, R. S., Rynes, E., Neph, S. J., Haugen, E., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.063 · Cited by 45
“A clone of the VHL-null 786-O RCC cell line stably transduced with VHL (786-O + VHL) and an empty vector (786-O + EV) control line [20] were obtained from Dr.”
MethodWierenga, A. T. J., Cunningham, A., Erdem, A., Vilaplana‐Lopera, N., Brouwers-Vos, A. Z., Pruis, M. G. M., Mulder, A. B., Günther, U. L., Martens, J. H. A., Vellenga, E., et al. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0206-y · Cited by 48
“The oxygen insensitive HIF mutants HIF1α(P402A,P564A)-EGFP and HIF2α(P405A, P531A)-EGFP (described previously in [40, 44]) were expressed as EGFP-fusion proteins in K562 cells.”
BackgroundRepression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth
Vindrieux, D., Devailly, G., Augert, A., Le Calvé, B., Ferrand, M., Pigny, P., Payen, L., Lambeau, G., Perrais, M., Aubert, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1681 · Cited by 42
“To determine whether HIFα protein degradation is involved in VHL-induced PLA2R1 transcription, we examined PLA2R1 transcript levels in ACHN (Figure 4D), RCC10+VHL (Figure 4E), and 786-O+VHL cells (Figure 4F) constitutively synthesizing a non-degradable form of either HIF1α or HIF2α [20].”
Hart, P. C., Kenny, H. A., Graßl, N., Watters, K. M., Litchfield, L. M., Coscia, F., Blaženović, I., Ploetzky, L., Fiehn, O., Mann, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.079 · Cited by 44
Shao, S., Zhao, L., An, G., Zhang, L., Jing, X., Luo, M., Li, W., Du, M., Ning, Q., Zhao, X., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000951rr · Cited by 46
Genetic causes of erythrocytosis and the oxygen-sensing pathway
Lee, F. S. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.04.003 · Cited by 47
Zhou, W., Dosey, T. L., Biechele, T. L., Moon, R. T., Horwitz, M. S., & Ruohola‐Baker, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027460 · Cited by 48
“To obtain constitutively stable expression HIFα protein, ndHIF over-expressing plasmids (Addgene plasmid 19005 and 19006) were used, in which two the Proline sites of HIF cDNA were changed to Alanine as described previously”
MethodRazorenova, O. V., Castellini, L., Colavitti, R., Edgington‐Mitchell, L. E., Nicolau, M., Huang, X., Bedogni, B., Mills, E., Bogyo, M. S., & Giaccia, A. J. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00644-12 · Cited by 44
Metabolic Rewiring in Response to Biguanides Is Mediated by mROS/HIF-1a in Malignant Lymphocytes
Khan, H., Anshu, A., Prasad, A. K., Roy, S., Jeffery, J. J., Kittipongdaja, W., Yang, D. T., & Schieke, S. M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.007 · Cited by 45
“…Healthcare Dharmacon, Inc. Cat#U-002000-05 crRNAs GE Healthcare Dharmacon, Inc. Cat#CR-004018-01 Recombinant DNA HA-HIF-1α P402A/P564A-pcDNA3 plasmid Yan et al., 2007 Addgene Plasmid#18955 Wildtype HA-HIF-1a-pcDNA3 plasmid Kondo et al., 2002 Addgene Plasmid#18949 Software and Algorithms Prism 8…”
Khan, M. N., Bhattacharyya, T., Andrikopoulos, P., Esteban, M. A., Barod, R., Connor, T., Ashcroft, M., Maxwell, P. H., & Kiriakidis, S. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.73 · Cited by 40
“This is further supported by data that mutating the FIH-1 target residue in HIF-2a did not increase its effect on HIF target genes or tumour growth in CCRCC cells, whereas substituting the equivalent residue in HIF-1a had a major effect (Yan et al, 2007).”
MethodWiesener, M. S., Münchenhagen, P., Gläser, M., Sobottka, B., Knaup, K. X., Jozefowski, K., Jürgensen, J. S., Roigas, J., Warnecke, C., Gröne, H., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22961 · Cited by 42
Dey, P., Velázquez‐Villegas, L. A., Faria, M., Turner, A. P. F., Jonsson, P., Webb, P., Williams, C., Gustafsson, J.-Å., & Ström, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128239 · Cited by 43
“[27, 28] in a 100 mm tissue culture plate.”
BackgroundHypoxia‐induced pulmonary hypertension—Utilizing experiments of nature
Gassmann, M., Cowburn, A. S., Gu, H., Li, J., Rodriguez, M., Babicheva, A., Jain, P., Xiong, M., Gassmann, N. N., Yuan, J. X. ‐., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15144 · Cited by 44
Pescador, N., Francisco, V., Vázquez, P., Esquinas-Román, E. M., González-Paramos, C., Valdecantos, M. P., García‐Martinez, I., Urrutia, A. A., Ruíz-Cañas, L., Escalona-Garrido, C., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102171 · Cited by 39
“This construct is constitutively active under normoxic conditions irrespective of the oxygen tension [40].”
Rosell-García, T., Palomo-Álvarez, O., & Rodríguez‐Pascual, F. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007674 · Cited by 36
“The vectors expressing constitutively active forms of human hypoxia-inducible factors HIF-1 (P402A/P564A-pcDNA3, N-terminally HA-tagged) and HIF-2 (P405A/P531A-pcDNA3, N-terminally HA-tagged) were a gift from William Kaelin (Addgene plasmids 18955 and 18956) (53).”
BackgroundAssociation of NRF2 with HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic condition
Hallis, S. P., Kim, S. K., Lee, J., & Kwak, M. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102632 · Cited by 40
“HIF-2α overexpression plasmid with mutation in its proline residues (pcDNA3-HA–HIF–2α-P405A/P531A) was a gift from William Kaelin (Addgene #18956) [33].”
MethodLiao, L., Liu, Z. Z., Langbein, L. E., Cai, W., Cho, E.-A., Na, J., Niu, X., Jiang, W., Zhong, Z., Cai, W. L., et al. (2018) · eLife · doi:10.7554/elife.37925 · Cited by 42
“The subcutaneous nude-mice xenograft assay was performed as described (Kondo et al., 2002; Yan et al., 2007).”
MethodSelf-citationDavid, J. M., Owens, T. A., Barwe, S. P., & Rajasekaran, A. K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0445 · Cited by 36
Loss of ATF4 leads to functional aging-like attrition of adult hematopoietic stem cells
Sun, Y., Lin, X., Liu, B., Zhang, Y., Li, W., Zhang, S., He, F., Tian, H., Zhu, X., Liu, X., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj6877 · Cited by 39
“To directly analyze the impact of HIF1 on the repopulating ability of ATF4−/− HSCs, we overexpressed HIF1 in isolated ATF4−/− Lin− cells by transducing them with control Babe-puro retrovirus (Babe virus) or Babe-puro-HIF1 retrovirus (HIF1 virus) (29, 30) (fig.”
Method
Metadata
- Authors
- Yan, Q., Bartz, S., Mao, M., Li, L., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Rosetta Inpharmatics, LLC.
- Corresponding author
- Kaelin, William G.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2007-03-01
- Volume
- 27
- Issue
- 6
- Pages
- 2092-2102
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC1820491
- OpenAlex
- W2161071327
- Cited by
- 193
- References
- 58
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 11 · 2021: 10 · 2020: 14 · 2019: 19 · 2018: 6 · 2017: 9 · 2016: 12 · 2015: 7 · 2014: 11 · 2013: 14 · 2012: 9
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Dana-Farber/Harvard Cancer Center
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- HIF-2α, hypoxia-inducible factor, N-terminal transactivation domain, C-terminal transactivation domain, renal carcinogenesis, kidney cancer, VHL, prolyl hydroxylation, transcriptional activation, hypoxia
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Amino Acid Sequence, Animals, Cell Line, Cell Transformation, Neoplastic, Humans, Kidney Neoplasms, Mice, Nude, Molecular Sequence Data, Mutation, Transcriptional Activation, Sequence Alignment, Conserved Sequence, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Rats, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.